Select a medication above to begin.
Femring
estradiol vaginal
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: RING: 0.05 mg per day, 0.1 mg per day
vasomotor symptoms, moderate-severe menopausal
- [insert ring PV q3mo]
- Start: 0.05 mg ring PV q3mo; Info: consider adding progestogen x10-14 days/4wk cycle if intact uterus; use lowest effective estrogen dose, shortest effective tx duration
vulvovaginal atrophy, menopausal
- [insert ring PV q3mo]
- Start: 0.05 mg ring PV q3mo; Info: consider adding progestogen x10-14 days/4wk cycle if intact uterus; use lowest effective estrogen dose, shortest effective tx duration; not preferred if local symptoms only
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.